2269.T
Meiji Holdings Co., Ltd. [2269.T] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
2269.T Stock Summary
Top 10 Correlated Stocks
2269.T
In the News
2269.T Financial details
Company Rating
Neutral
Market Cap
930.54B
Income
67.09B
Revenue
1097.08B
Book val./share
2691.94
Cash/share
344.07
Dividend
95
Dividend %
2.71%
Employees
17.29K
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
15.29
Forward P/E
-
PEG
-7.34
P/S
0.89
P/B
1.31
P/C
9.98
P/FCF
43.66
Quick Ratio
0.91
Current Ratio
1.78
Debt / Equity
0.11
LT Debt / Equity
0.06
-
-
EPS (TTM)
240.39
EPS next Y
-
EPS next Q
-
EPS this Y
-18.52%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
3.01%
Revenue last 5Y
-3.27%
Revenue Q/Q
1.29%
EPS Q/Q
4.22%
-
-
-
-
SMA20
-1.61%
SMA50
-6.04%
SMA100
-0.8%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
9%
ROC
0.08%
Gross Margin
29%
Oper. Margin
7%
Profit Margin
6%
Payout
39%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3100.0-3823.0
52W High
-10.15%
52W Low
+10.81%
RSI
55
Rel Volume
1.4
Avg Volume
968.96K
Volume
1.36M
Perf Week
2.84%
Perf Month
1.63%
Perf Quarter
-7.16%
Perf Half Y
-5.74%
-
-
-
-
Beta
0.03
-
-
Volatility
42.36%, 42.21%
Prev Close
1.15%
Price
3435
Change
1.84%
2269.T Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.32K | 4.32K | 4.11K | 3.55K | 3.78K | |
| Net income per share | 213.3 | 232.04 | 226.26 | 306.57 | 247.38 | |
| Operating cash flow per share | 386.49 | 393.3 | 426.23 | 446.82 | 302.93 | |
| Free cash flow per share | 140.87 | 148.13 | 192.24 | 120.39 | 45.76 | |
| Cash per share | -8.21 | 51.15 | 31.01 | 134.88 | 123.06 | |
| Book value per share | 1.82K | 1.94K | 2.14K | 2.36K | 2.54K | |
| Tangible book value per share | 1.89K | 2.01K | 2.22K | 2.43K | 2.6K | |
| Share holders equity per share | 1.82K | 1.94K | 2.14K | 2.36K | 2.54K | |
| Interest debt per share | 403.95 | 370.48 | 352.88 | 286.49 | 231.02 | |
| Market cap | 1322.61B | 1114.05B | 1033.03B | 943.27B | 885.4B | |
| Enterprise value | 1413.64B | 1183.36B | 1094.48B | 957.12B | 886.25B | |
| P/E ratio | 21.38 | 16.55 | 15.73 | 10.78 | 12.75 | |
| Price to sales ratio | 1.05 | 0.89 | 0.87 | 0.93 | 0.83 | |
| POCF ratio | 11.8 | 9.76 | 8.35 | 7.4 | 10.41 | |
| PFCF ratio | 32.37 | 25.92 | 18.52 | 27.45 | 68.94 | |
| P/B Ratio | 2.51 | 1.98 | 1.66 | 1.4 | 1.24 | |
| PTB ratio | 2.51 | 1.98 | 1.66 | 1.4 | 1.24 | |
| EV to sales | 1.13 | 0.94 | 0.92 | 0.94 | 0.83 | |
| Enterprise value over EBITDA | 9.74 | 7.94 | 6.87 | 6.62 | 6.91 | |
| EV to operating cash flow | 12.61 | 10.37 | 8.85 | 7.51 | 10.42 | |
| EV to free cash flow | 34.6 | 27.54 | 19.62 | 27.85 | 69.01 | |
| Earnings yield | 0.05 | 0.06 | 0.06 | 0.09 | 0.08 | |
| Free cash flow yield | 0.03 | 0.04 | 0.05 | 0.04 | 0.01 | |
| Debt to equity | 0.22 | 0.19 | 0.16 | 0.12 | 0.09 | |
| Debt to assets | 0.12 | 0.11 | 0.1 | 0.07 | 0.06 | |
| Net debt to EBITDA | 0.63 | 0.47 | 0.39 | 0.1 | 0.01 | |
| Current ratio | 1.45 | 1.63 | 1.68 | 1.59 | 1.77 | |
| Interest coverage | 126.46 | 143.25 | 170.52 | 185.84 | 163.27 | |
| Income quality | 1.19 | 1.17 | 1.2 | 0.99 | 0.89 | |
| Dividend Yield | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
| Payout ratio | 0.32 | 0.31 | 0.34 | 0.27 | 0.35 | |
| Sales general and administrative to revenue | 0.16 | 0.17 | 0.17 | 0.17 | 0.16 | |
| Research and developement to revenue | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.64 | -0.62 | -0.55 | -0.73 | -0.85 | |
| Capex to revenue | -0.06 | -0.06 | -0.06 | -0.09 | -0.07 | |
| Capex to depreciation | -1.59 | -1.54 | -1.4 | -1.86 | -1.35 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.95K | 3.18K | 3.3K | 4.03K | 3.76K | |
| ROIC | 0.1 | 0.11 | 0.1 | 0.09 | 0.07 | |
| Return on tangible assets | 0.06 | 0.07 | 0.06 | 0.08 | 0.06 | |
| Graham Net | -728.46 | -567.48 | -600.85 | -500.93 | -430.62 | |
| Working capital | 129.94B | 160.37B | 173.04B | 168.8B | 204.66B | |
| Tangible asset value | 547.08B | 583.55B | 643.37B | 694.87B | 729.81B | |
| Net current asset value | -22.07B | 15.81B | 18.41B | 51.17B | 86.01B | |
| Invested capital | 0.22 | 0.19 | 0.16 | 0.12 | 0.09 | |
| Average receivables | 203.81B | 191.06B | 178.83B | 175.84B | 173.48B | |
| Average payables | 122.79B | 118.9B | 108.65B | 106.3B | 109.97B | |
| Average inventory | 151.2B | 169.61B | 177.64B | 183.51B | 192.29B | |
| Days sales outstanding | 58.83 | 52.43 | 54.43 | 62.67 | 59.45 | |
| Days payables outstanding | 57.41 | 51.88 | 51.63 | 56.95 | 54.27 | |
| Days of inventory on hand | 75.91 | 80.05 | 89.51 | 97.9 | 96.43 | |
| Receivables turnover | 6.2 | 6.96 | 6.71 | 5.82 | 6.14 | |
| Payables turnover | 6.36 | 7.04 | 7.07 | 6.41 | 6.73 | |
| Inventory turnover | 4.81 | 4.56 | 4.08 | 3.73 | 3.79 | |
| ROE | 0.12 | 0.12 | 0.11 | 0.13 | 0.1 | |
| Capex per share | -245.62 | -245.17 | -233.99 | -326.43 | -257.17 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1K | 947.25 | 942.45 | 1.02K | 1.03K | |
| Net income per share | 49.57 | 79.42 | 41.59 | 58.54 | 61 | |
| Operating cash flow per share | 41.14 | 173.32 | 8.62 | 84.24 | 138.43 | |
| Free cash flow per share | -22.83 | 99.28 | -42.09 | 45.11 | 83.34 | |
| Cash per share | 226.94 | 149.89 | 196.66 | 214.33 | 344.07 | |
| Book value per share | 2.52K | 2.55K | 2.59K | 2.67K | 2.69K | |
| Tangible book value per share | 2.6K | 2.62K | 2.66K | 2.74K | 2.77K | |
| Share holders equity per share | 2.52K | 2.55K | 2.59K | 2.67K | 2.69K | |
| Interest debt per share | 496.13 | 231.26 | 364.37 | 295.49 | 291.15 | |
| Market cap | 944.86B | 879.55B | 897.11B | 1036.47B | 934.73B | |
| Enterprise value | 996.12B | 880.41B | 914.53B | 1036.71B | 923.63B | |
| P/E ratio | 17 | 9.93 | 19.35 | 15.87 | 13.73 | |
| Price to sales ratio | 3.37 | 3.33 | 3.41 | 3.66 | 3.26 | |
| POCF ratio | 81.92 | 18.2 | 373.33 | 44.11 | 24.19 | |
| PFCF ratio | -147.61 | 31.78 | -76.45 | 82.38 | 40.18 | |
| P/B Ratio | 1.34 | 1.24 | 1.24 | 1.39 | 1.24 | |
| PTB ratio | 1.34 | 1.24 | 1.24 | 1.39 | 1.24 | |
| EV to sales | 3.55 | 3.33 | 3.48 | 3.66 | 3.22 | |
| Enterprise value over EBITDA | 27.5 | 40.69 | 27.88 | 27.49 | 23.48 | |
| EV to operating cash flow | 86.36 | 18.22 | 380.58 | 44.12 | 23.9 | |
| EV to free cash flow | -155.62 | 31.81 | -77.94 | 82.4 | 39.71 | |
| Earnings yield | 0.01 | 0.03 | 0.01 | 0.02 | 0.02 | |
| Free cash flow yield | -0.01 | 0.03 | -0.01 | 0.01 | 0.02 | |
| Debt to equity | 0.2 | 0.09 | 0.14 | 0.11 | 0.11 | |
| Debt to assets | 0.11 | 0.06 | 0.09 | 0.07 | 0.07 | |
| Net debt to EBITDA | 1.41 | 0.04 | 0.53 | 0.01 | -0.28 | |
| Current ratio | 1.52 | 1.77 | 1.73 | 1.78 | 1.72 | |
| Interest coverage | 181.06 | 104.84 | 207.41 | 230.98 | 277.68 | |
| Income quality | 0.56 | 1.83 | 0.11 | 0.92 | 1.49 | |
| Dividend Yield | 0.01 | 0 | 0.01 | 0 | 0.01 | |
| Payout ratio | 0.86 | 0 | 1.12 | 0.01 | 0.79 | |
| Sales general and administrative to revenue | 0 | 0.05 | 0 | 0.13 | 0 | |
| Research and developement to revenue | 0.02 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -1.55 | -0.43 | -5.88 | -0.46 | -0.4 | |
| Capex to revenue | -0.06 | -0.08 | -0.05 | -0.04 | -0.05 | |
| Capex to depreciation | -1.31 | -1.5 | -1.05 | -0.82 | -1.07 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.68K | 2.14K | 1.56K | 1.88K | 1.92K | |
| ROIC | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Return on tangible assets | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Graham Net | -502.76 | -407.47 | -442.66 | -352.38 | -287.8 | |
| Working capital | 183.8B | 204.66B | 211.44B | 235.44B | 234.28B | |
| Tangible asset value | 729.55B | 729.81B | 740.56B | 764.85B | 772.17B | |
| Net current asset value | 73.66B | 86.01B | 93.15B | 116.93B | 116.5B | |
| Invested capital | 0.2 | 0.09 | 0.14 | 0.11 | 0.11 | |
| Average receivables | 202.2B | 195.38B | 171.81B | 192.55B | 218.35B | |
| Average payables | 112.46B | 116.73B | 110.66B | 116.5B | 124.25B | |
| Average inventory | 200.04B | 198.7B | 203.27B | 205.67B | 201.66B | |
| Days sales outstanding | 69.85 | 58.96 | 58.44 | 68.13 | 69.7 | |
| Days payables outstanding | 54.18 | 52.63 | 52.62 | 56.62 | 55.53 | |
| Days of inventory on hand | 88.48 | 93.5 | 99.9 | 93.33 | 88.73 | |
| Receivables turnover | 1.29 | 1.53 | 1.54 | 1.32 | 1.29 | |
| Payables turnover | 1.66 | 1.71 | 1.71 | 1.59 | 1.62 | |
| Inventory turnover | 1.02 | 0.96 | 0.9 | 0.96 | 1.01 | |
| ROE | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Capex per share | -63.97 | -74.04 | -50.71 | -39.13 | -55.09 |
2269.T Frequently Asked Questions
What is Meiji Holdings Co., Ltd. stock symbol ?
Meiji Holdings Co., Ltd. is a JP stock and trading under the symbol 2269.T
What is Meiji Holdings Co., Ltd. stock quote today ?
Meiji Holdings Co., Ltd. stock price is $3435 today.
Is Meiji Holdings Co., Ltd. stock public?
Yes, Meiji Holdings Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 968.96K
- Market Capitalization 930.54B
- Employee 17.29K
- CEO Mr. Kazuo Kawamura
- Headquarters Tokyo,JP
- IPO Date 2000-01-04
-
Website
https://www.meiji.com 
Meiji Holdings Co., Ltd., through its subsidiaries, manufactures and sells dairy products, confectioneries, nutritional products, and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceutical. It provides yogurt, drinking milk, beverages, cheese, butter and margarine, cream, ice cream, frozen foods, chocolates, gummy products, chewing gums, candies, sports nutrition products, infant and eternal formula, beauty supplements, OTC drugs, livestock products, and sugar, as well as transportation and distribution services. The company also provides drugs for infectious diseases and central nervous system disorders, as well as generic drugs; agricultural and livestock chemicals; human and veterinary vaccines, and blood plasma products; and veterinary drugs for livestock and fisheries comprising antimicrobial injection, oral administration, antipyretic, analgesic, anti-inflammatory, hemostatic, and breeding agents, disinfectants, insecticides, anthelmintics, metabolites, feed additives, and mixed feed; and companion animals, including anesthetics and painkillers, anti-parasitic and gastrointestinal drugs, anti-bacterial agents, antiplasmin agents, vitamin E preparations, and dietary supplements. Meiji Holdings Co., Ltd. was founded in 1916 and is headquartered in Tokyo, Japan.
